Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Approves Two New Indications For Edwards’ Sapien 3 TAVR System

Executive Summary

Sapien 3 is now indicated to treat failed right ventricular outflow tract conduits, surgical bioprosthetic pulmonary valves and transcatheter aortic valves.

You may also be interested in...



FDA Approves Edwards’ Sapien 3 With The Alterra Prestent For Pulmonary Regurgitation

The new device combines Edwards’ market-leading Sapien 3 transcatheter heart valve with its Alterra adaptive prestent device to treat patients with severe pulmonary regurgitation due to congenital valve defects.

Medtronic’s Transcatheter Harmony Valve For Congenital Pulmonary Defect Wins FDA Approval

The Harmony transcatheter pulmonary valve can be used to improve blood flow to the lungs in patients with severe pulmonary valve regurgitation as a result of a congenital malformation of the right ventricular outflow tract.

Edwards Beat Analysts' And Its Own Projections in Q2 As TAVR Volumes Recover

The company recorded $925m in revenue in the second quarter of 2020, exceeding the top end of its previous guidance, and expects to return to growth by the end of the year.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT142735

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel